Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 18Breast Neoplasms 10Stomach Neoplasms 9Ovarian Neoplasms 8Prostatic Neoplasms 7Colorectal Neoplasms 6Cholangiocarcinoma 5Glioma 4Sarcoma 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Esophageal Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Bile Duct Neoplasms 2Xanthogranuloma, Juvenile 1Thrombocytosis 1Sarcoma, Ewing 1

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian × olaparib × Gastrointestinal × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡